Huili Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huili Su has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Conggang Zhang
School of Pharmaceutical Sciences, State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China
19 shared publications - Jing Han
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
19 shared publications - Peng Liu
School of Biomedical Engineering, Tsinghua Medicine, Tsinghua University, Beijing, China
19 shared publications - Shuiqing Hu
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas
19 shared publications - Xuxu Sun
Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
19 shared publications - Yanfei Hou
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
19 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Figures S1 to S9 with Legends
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Figures S1 to S9 with Legends
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Cyclic GMP–AMP (cGAMP) is a second messenger that activates the stimulator of interferon genes (STING) innate immune pathway to induce the expression of type I IFNs and other cytokines. Pharmacologic activation of STING is considered a potent therapeutic strategy in cancer. In this study, we used a cell-based phenotypic screen and identified podophyllotoxin (podofilox), a microtubule destabilizer, as a robust enhancer of the cGAMP–STING signaling pathway. We found that podofilox enhanced the cGAMP-mediated immune response by increasing STING-containing membrane puncta and the extent of STING oligomerization. Furthermore, podofilox changed the trafficking pattern of STING and delayed trafficking-mediated STING degradation. Importantly, the combination of cGAMP and podofilox had profound antitumor effects on mice by activating the immune response through host STING signaling. Together, these data provide insights into the regulation of cGAMP–STING pathway activation and demonstrate what we believe to be a novel approach for modulating this pathway and thereby promoting antitumor immunity.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Cyclic GMP–AMP (cGAMP) is a second messenger that activates the stimulator of interferon genes (STING) innate immune pathway to induce the expression of type I IFNs and other cytokines. Pharmacologic activation of STING is considered a potent therapeutic strategy in cancer. In this study, we used a cell-based phenotypic screen and identified podophyllotoxin (podofilox), a microtubule destabilizer, as a robust enhancer of the cGAMP–STING signaling pathway. We found that podofilox enhanced the cGAMP-mediated immune response by increasing STING-containing membrane puncta and the extent of STING oligomerization. Furthermore, podofilox changed the trafficking pattern of STING and delayed trafficking-mediated STING degradation. Importantly, the combination of cGAMP and podofilox had profound antitumor effects on mice by activating the immune response through host STING signaling. Together, these data provide insights into the regulation of cGAMP–STING pathway activation and demonstrate what we believe to be a novel approach for modulating this pathway and thereby promoting antitumor immunity.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Cyclic GMP–AMP (cGAMP) is a second messenger that activates the stimulator of interferon genes (STING) innate immune pathway to induce the expression of type I interferons (IFNs) and other cytokines. Pharmacological activation of STING is considered a potent therapeutic strategy in cancer. In this study, we employed a cell-based phenotypic screen and identified podophyllotoxin (podofilox), a microtubule destabilizer, as a robust enhancer of the cGAMP–STING signaling pathway. We found that podofilox enhanced the cGAMP-mediated immune response by increasing STING-containing membrane puncta and the extent of STING oligomerization. Furthermore, podofilox changed the trafficking pattern of STING and delayed trafficking-mediated STING degradation. Importantly, the combination of cGAMP and podofilox had profound antitumor effects on mice by activating the immune response through host STING signaling. Together, these data provide insights into the regulation of cGAMP–STING pathway activation and demonstrate what we believe to be a novel approach for modulating this pathway and thereby promoting antitumor immunity.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Cyclic GMP–AMP (cGAMP) is a second messenger that activates the stimulator of interferon genes (STING) innate immune pathway to induce the expression of type I interferons (IFNs) and other cytokines. Pharmacological activation of STING is considered a potent therapeutic strategy in cancer. In this study, we employed a cell-based phenotypic screen and identified podophyllotoxin (podofilox), a microtubule destabilizer, as a robust enhancer of the cGAMP–STING signaling pathway. We found that podofilox enhanced the cGAMP-mediated immune response by increasing STING-containing membrane puncta and the extent of STING oligomerization. Furthermore, podofilox changed the trafficking pattern of STING and delayed trafficking-mediated STING degradation. Importantly, the combination of cGAMP and podofilox had profound antitumor effects on mice by activating the immune response through host STING signaling. Together, these data provide insights into the regulation of cGAMP–STING pathway activation and demonstrate what we believe to be a novel approach for modulating this pathway and thereby promoting antitumor immunity.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Supplementary Figures S1 to S9 with Legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Supplementary Figures S1 to S9 with Legends
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Supplementary Figures S1 to S9 with Legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Supplementary Figures S1 to S9 with Legends
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Movie from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Movie from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Supplementary Movie from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Supplementary Movie from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
- Open Access
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
- Open Access
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity